Trump Speeds Psychedelic Reviews, Including Ibogaine, for Treasure Coast Vets' PTSD

President Donald Trump signed an executive order Saturday directing his administration to accelerate federal review of psychedelic drugs — including ibogaine, a plant-derived compound embraced by combat veterans but linked to serious cardiac risks — in a move that could reshape mental health treatment options for Treasure Coast residents.

The order directs the Department of Health and Human Services to channel at least $50 million to states that have enacted or are developing programs to advance psychedelic drugs for serious mental illness. The Food and Drug Administration will issue national priority vouchers next week for three psychedelics, FDA Commissioner Marty Makary said, potentially cutting review timelines from several months to weeks. This marks the first time the FDA has offered that accelerated pathway to any psychedelic substance. The FDA is also clearing the way for the first-ever human trials of ibogaine in the United States.

For Treasure Coast veterans — Martin, St. Lucie and Indian River counties are home to a significant active and retired military population — the order arrives amid a years-long, out-of-pocket exodus to ibogaine clinics in Mexico. U.S. veterans have sought treatment there for PTSD and opioid addiction at costs ranging from $15,000 to $20,000 per session. No insurance coverage exists for the treatment, and that will not change immediately under Saturday's order, clinic operators cautioned.

"There will be no insurance coverage, it will still be considered unapproved and non-covered care," said Tom Feegel of Beond Ibogaine, which operates a clinic in Cancun, Mexico and treated roughly two thousand patients last year, including approximately one hundred veterans at no charge. "But what it does mean is that ibogaine shifts from being fringe and underground to being federally acknowledged."

The order drew praise from veteran advocates but caution from researchers. Ibogaine, derived from a shrub native to West Africa, has been linked to more than thirty deaths in medical literature and is known to trigger potentially fatal irregular heart rhythms, according to the Multidisciplinary Association for Psychedelic Studies. The National Institutes of Health funded early ibogaine research in the nineteen nineties before halting it over what officials described as the drug's "cardiovascular toxicity."

"It's been incredibly difficult to study ibogaine in the U.S. because of its known cardiotoxicity," said Frederick Barrett, director of the Johns Hopkins Center for Psychedelic and Consciousness Research. "If the executive order can pave the way for doing objective, scientific research with this compound, it would help us understand whether it is truly a better psychedelic therapy than others."

Ibogaine and all other psychedelics remain Schedule I controlled substances — the federal government's most restrictive classification, alongside heroin — and no psychedelic has received FDA approval in the United States.

Trump was joined at the signing by Health Secretary Robert F. Kennedy Jr., conservative podcaster Joe Rogan and Marcus Luttrell, the former Navy SEAL whose survival story inspired the film "Lone Survivor." Luttrell told the president the drug "absolutely changed my life for the better." Rogan said he had texted Trump information about ibogaine and received the reply: "Sounds great. Do you want FDA approval? Let's do it."

The Multidisciplinary Association for Psychedelic Studies' co-executive director, Ismail Lourido Ali, said the order could prompt Republican-led states, including Florida, to fund university research programs modeled on a Texas law passed last year that allocated $50 million for ibogaine research. "The stigma around Schedule I drugs is significant," Ali said. "It feels like this would give pretty substantial cover for Republican governors and legislatures to step into the ring."

Florida's congressional delegation had not issued formal responses to the order as of Saturday afternoon. Rep. Brian Mast, R-Fla., an Army combat veteran who lost both legs in Afghanistan, has previously expressed openness to psychedelic-assisted therapies for veterans.

The FDA's priority voucher program and HHS funding framework are expected to take effect in the coming weeks, officials said.

This article was generated with AI assistance using publicly available information. It was reviewed and approved by a human editor before publication. TC Sentinel uses AI writing tools in accordance with FTC guidelines.